Thank you very much for joining us today Mr Niel Marotta, CEO @ INDIVA. We have been monitoring INDIVA since June and love seeing how the story has progressed. Can you please tell us a little about your company and where you are today?

INDIVA is a Licensed Producer under the ACMPR. We received our Cultivation License in July of 2017 and began cultivation in September 2017. We expect to complete our first harvest early in 2018. We also just completed a $23 million capital raise, which fully funds our expansion to 40,000 square feet. We are now trading on the TSX Venture Exchange under NDVA.

Going forward, what initiatives are you most focused on and which will be most beneficial for the company’s long-term outlook.

First and foremost is our effort to create high quality medicinal cannabis for our clients, which we expect to begin onboarding in 2018. We will invest some $10 million into the expansion of our facility as well, which will increase our annual dry-flower production capacity 10-fold. We will also construct an oil extraction room at our facility. We believe oils, gel caps, and eventually other derivative products will remain in high demand and offer significant upside to the number of clients we can serve. INDIVA’s ambitions go well beyond the footprint our first facility. We are currently evaluating several options for further expansion. We are also close to completing agreements with international partners, which will give us access to new genetics as well as the possibility to export outside of Canada and access foreign markets.

What do you think about what has happened with Canada’s legal cannabis industry and where do you see it going in 2018?

We are excited to see the progress towards the beginning of the recreational market in Canada in 2018, and INDIVA will certainly embrace this distribution channel. Perhaps as exciting is the recent Health Canada proposal, which indicates that in the relative near term Licensed Producers will be permitted to offer a much greater breadth of product, particularly in the derivate space (i.e. edibles etc.). So overall it is very encouraging that the market continues to grow rapidly in size and scope.

Tell us a little about the transaction with Rainmaker Resources (RIR.V). How did this come to fruition and where does it stand?

INDIVA completed the RTO transaction with Rainmaker Resources in December 2017, so the primary business of the company, including the management team and board are now that of INDIVA. We completed a $23 million financing concurrent with this transaction, and INDIVA is now listed and trading on the TSX Venture Exchange under the ticker NDVA.

Your company manifesto is “our experience is growing”. Can you elaborate on that and how this mantra resonates throughout your business?

Our corporate ethos revolves around quality, authenticity and experience. As such, our facility is an indoor-grow facility and great attention has ben paid to keeping a pristine production environment. Our production team has decades of combined experience legally growing medical marijuana in an indoor-grow environment, and we believe this experience and methodology will result in the highest grade medicinal product for our clients. This experience also extends to client care and we are thankful to have a great team at INDIVA with this know-how.

We have received inquiries from investors asking about your private placement. Does INDIVA have an offering that is open? Can you tell us about the previously completed financings?

Our financing is now closed. We completed $12 million of equity financing plus an additional $11 million through a convertible debenture placement.

What is the companies current production capacity and what do you expect it to be by the end of the year?

Currently our annual dry flower production capacity is 250-300 kgs. We expect that by the end of 2018, once our expansion is complete, our annual capacity will be some 2,500-3,000 kgs. This projection excludes any production of oil from our extraction room, which adds upside to our expectations.

What aspects of the legal cannabis industry is INDIVA focused on and where does it see the most growth potential?

We will always produce a high-quality medical grade product for our clients, regardless of whether it is dry flowers, oils or any other derivative product the law permits us to produce and sell. We believe there will always be clients who wish to smoke or vape dry flowers, however, we very are excited about the derivative market. We believe there is tremendous opportunity to create products for our clients containing THC, and some strictly with CBD, which can be consumed orally or perhaps applied as a topical. We are excited to see the anticipated changes in the regulations in this area because this opens up our market to potentially new clients who perhaps never considered using cannabis, or simply may prefer not to smoke or vape cannabis. INIDVA is an inclusive brand and we think these changes are exciting both for the medical as well as the recreational market.